Genocea Biosciences Inc Revenue Growth Rates (GNCA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Genocea Biosciences Inc   (NASDAQ: GNCA)
 

GNCA's Revenue Growth by Quarter and Year

Genocea Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNCA Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.27
FY 0.27





GNCA Revenue first quarter 2022 Y/Y Growth Comment
Genocea Biosciences Inc reported drop in Revenue in the first quarter 2022 by -68.24% to $ 0.27 millions, from the same quarter in 2021.
The fall in the first quarter 2022 Genocea Biosciences Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 54.88%.

Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Revenue growth. While Genocea Biosciences Inc ' s Revenue meltdown of -68.24% ranks overall at the positon no. 3806 in the first quarter 2022.


GNCA Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - - - -
3rd Quarter September - -10.7 % 407.69 % -23.53 %
2nd Quarter June - 830.97 % -70.8 % -29.64 %
1st Quarter March -68.24 % 8.97 % - -
FY   - 62.91 % 4427.59 % -

Financial Statements
Genocea Biosciences Inc 's first quarter 2022 Revenue $ 0.27 millions GNCA's Income Statement
Genocea Biosciences Inc 's first quarter 2021 Revenue $ 0.85 millions Quarterly GNCA's Income Statement


GNCA Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - - - -
3rd Quarter September - -4.75 % 892.92 % -42.89 %
2nd Quarter June - 1137.65 % 44.87 % -
1st Quarter March - - - -
FY (Year on Year)   - 62.91 % 4427.59 % -


Back to GNCA Growth rate Comparisons >> Back to GNCA Growth rate Comparisons >>


Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #589
Overall #3806

Revenue Y/Y Growth Statistics
High Average Low
832.36 % 54.88 % -100 %
(Jun 30 2021)   (Jun 30 2019)
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #589
Overall #3806
Revenue Y/Y Growth Statistics
High Average Low
832.36 % 54.88 % -100 %
(Jun 30 2021)   (Jun 30 2019)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Genocea Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1131.5 % 109.12 % -100 %
(Jun 30 2021)  


GNCA's I. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #61
Healthcare Sector #549
Overall #3527
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #61
Healthcare Sector #549
Overall #3527
Revenue Q/Q Growth Statistics
High Average Low
1131.5 % 109.12 % -100 %
(Jun 30 2021)  


GNCA's I. Quarter Q/Q Revenue Comment


Genocea Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)
Cumulative Revenue 12 Months Ending $ 21.20 $ 21.78 $ 18.51 $ 19.71 $ 10.32
Y / Y Revenue Growth (TTM) 105.38 % 112.54 % 4.62 % 127.02 % -
Year on Year Revenue Growth Overall Ranking # 137 # 163 # 453 # 217 # 0
Seqeuential Revenue Change (TTM) -2.68 % 17.65 % -6.07 % 90.97 % 0.71 %
Seq. Revenue Growth (TTM) Overall Ranking # 2976 # 418 # 636 # 39 # 371


Cumulative Revenue growth Comment
Assuming the Genocea Biosciences Inc 's fiscal year would have ended in Mar 31 2022, Genocea Biosciences Inc would have reprted above average annual Revenue surge of 105.38% year on year, of $ 21 millions.
This marks a slow-down of the companys growth trends and from the 112.54% surge in Dec 31 2021.

Among companies within the Healthcare sector 17 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 137, from total ranking in previous quarter at 163.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 18
Overall # 137

Revenue TTM Y/Y Growth Statistics
High Average Low
127.02 %
 87.39 %
4.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 410
S&P 500 # 2976
Cumulative Revenue growth Comment
Assuming the Genocea Biosciences Inc 's fiscal year would have ended in Mar 31 2022, Genocea Biosciences Inc would have reprted above average annual Revenue surge of 105.38% year on year, of $ 21 millions.
This marks a slow-down of the companys growth trends and from the 112.54% surge in Dec 31 2021.

Among companies within the Healthcare sector 17 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 137, from total ranking in previous quarter at 163.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 18
Overall # 137

Revenue TTM Y/Y Growth Statistics
High Average Low
127.02 %
87.39 %
4.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 410
S&P 500 # 2976




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GNCA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2022
Sage Therapeutics Inc -0.06%$ -0.063 millions
Davita Inc -0.09%$ -0.087 millions
Axogen inc -0.10%$ -0.097 millions
Musclepharm Corporation-0.15%$ -0.152 millions
3m Company-0.25%$ -0.249 millions
Oncternal Therapeutics Inc -0.27%$ -0.267 millions
Glaukos Corp-0.42%$ -0.422 millions
Collegium Pharmaceutical Inc -0.70%$ -0.699 millions
Tenet Healthcare Corp-0.75%$ -0.753 millions
Nevro Corp -0.87%$ -0.867 millions
Antares Pharma Inc -1.25%$ -1.250 millions
Assure Holdings Corp -1.34%$ -1.343 millions
Elanco Animal Health Incorporated-1.37%$ -1.369 millions
Longeveron Inc -1.60%$ -1.596 millions
Rockwell Medical inc -1.67%$ -1.674 millions
Nanostring Technologies Inc -1.70%$ -1.698 millions
Mimedx Group Inc -1.79%$ -1.789 millions
Exagen Inc -1.82%$ -1.823 millions
Cryoport inc -1.84%$ -1.843 millions
Royalty Pharma Plc-1.92%$ -1.916 millions
Veru Inc -2.34%$ -2.339 millions
Femasys Inc -2.55%$ -2.545 millions
Delcath Systems Inc -2.58%$ -2.577 millions
Imagenebio Inc -2.59%$ -2.591 millions
Therapeuticsmd Inc -2.68%$ -2.683 millions
Ngm Biopharmaceuticals Inc -2.91%$ -2.906 millions
Livanova Plc-3.00%$ -3.000 millions
Lifevantage Corp-3.04%$ -3.037 millions
Reata Pharmaceuticals Inc -3.18%$ -3.178 millions
Becton Dickinson And Company-3.20%$ -3.200 millions


About Genocea Biosciences Inc Revenue Growth Rates (GNCA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Genocea Biosciences Inc (CIK 1457612).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001457612-22-000054
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Genocea Biosciences Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.